Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 12INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Neoplasms 2870Carcinoma, Non-Small-Cell Lung 2420Breast Neoplasms 2065Colorectal Neoplasms 1239Neoplasm Metastasis 1223Prostatic Neoplasms 1076Melanoma 972Multiple Myeloma 960Ovarian Neoplasms 899Recurrence 849Leukemia, Myeloid, Acute 807Lung Neoplasms 756Pancreatic Neoplasms 750Lymphoma, Non-Hodgkin 726Lymphoma 660Stomach Neoplasms 622Carcinoma, Hepatocellular 564Carcinoma, Renal Cell 544Squamous Cell Carcinoma of Head and Neck 525Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 449Glioblastoma 435Advanced Solid Tumors 430Small Cell Lung Carcinoma 408Triple Negative Breast Neoplasms 407Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 367Advanced Solid Tumor 349

Interventions

sintilimab 1pembrolizumab 1durvalumab 1Injections 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Advanced Biliary Tract Cancer × Clear all
NCT07229625 2026-01-28

A Phase III Study of SHR-8068 in Combination With Adebrelimab and Platinum-Containing Chemotherapy Versus Durvalumab in Combination With Platinum-Containing Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer (BTC)

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
604 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT06978114 2025-07-02

A Study of BL-B01D1+PD-1/PD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
46 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT05653180 2023-04-03

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Unknown
20 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

NCT02597465 2020-12-14

A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507

Sun Pharma Advanced Research Company Limited

Phase 3 Withdrawn
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡